MOLECULAR PHARMACOLOGY, published by the American Society for Pharmacology and Experimental Therapeutics, is an influential peer-reviewed journal dedicated to advancing the field of pharmacology through comprehensive research on molecular mechanisms of drug action. With an impressive historic convergence from 1965 to 2024, this journal plays a pivotal role in disseminating high-quality research, showcasing significant findings that impact both clinical and experimental pharmacology. Notably, it holds a distinguished Q1 ranking in Pharmacology and a Q2 ranking in Molecular Medicine as of 2023, reflecting its prominence in the academic community. Researchers and practitioners engaged in pharmacological studies will benefit from the journal’s focus on new therapeutic strategies, drug development, and the molecular basis of drug action. While MOLECULAR PHARMACOLOGY is not an open-access journal, it offers a wealth of knowledge behind a subscription model, ensuring that contributors and readers maintain a high standard of academic rigor. Address all inquiries to the editorial office located at 9650 Rockville Pike, Bethesda, MD 20814-3995, United States.

MOLECULAR THERAPY, published by CELL PRESS, is a distinguished journal in the field of molecular biology and therapy, renowned for its significant contributions to drug discovery, genetics, and pharmacology since its inception in 2000. This prestigious journal, which holds a commendable position in the Q1 category across multiple disciplines including Drug Discovery, Molecular Medicine, and Molecular Biology, facilitates cutting-edge research and innovative therapies that aim to improve patient outcomes. With an impressive Scopus ranking that places it among the top journals in its field—such as rank #6 in Drug Discovery and #8 in Pharmacology—MOLECULAR THERAPY is crucial for researchers, professionals, and students seeking to advance their understanding and application of molecular techniques. The journal welcomes high-quality submissions that explore the therapeutic potential of molecular mechanisms, fostering a collaborative spirit within the scientific community to push the boundaries of modern medicine.

Archives of Pharmacal Research, published by the Pharmaceutical Society of Korea, is a leading journal in the fields of drug discovery, molecular medicine, and organic chemistry. With an illustrious history spanning from 1978 to 2024, this peer-reviewed journal has earned a remarkable reputation, achieving a Q1 category ranking in each of its primary research areas as of 2023. Ranked #9 in Organic Chemistry and #12 in Drug Discovery among their respective fields, Archives of Pharmacal Research showcases cutting-edge research that contributes significantly to scientific advancements. Although it is not an open-access journal, its impactful publications are crucial resources for researchers, professionals, and students navigating the complexities of pharmacological sciences. The journal's continued commitment to disseminating high-quality research underlines its importance in fostering innovation and expanding knowledge within the pharmaceutical landscape.

PHARMACEUTICAL BIOLOGY, published by Taylor & Francis Ltd, is a prominent open-access journal that has been a cornerstone of research in the life sciences since its convergence in 1961. With a strong focus on Complementary and Alternative Medicine, Pharmaceutical Science, and Drug Discovery, this journal is dedicated to disseminating groundbreaking research that intersects pharmaceuticals and biology. Acknowledged for its rigorous peer-review process, it holds a prestigious Q1 ranking in Pharmaceutical Science and exemplifies the commitment to quality and impact in the field, boasting an impressive Scopus rank of #14/105 in the complementary and alternative medicine category. Researchers keen on advancing their knowledge in these fields will find PHARMACEUTICAL BIOLOGY an invaluable resource, offering accessibility since its shift to open access in 2017. This journal presents a platform for innovative studies that contribute to the evolving understanding of pharmaceutical applications and biological interactions, serving as an essential hub for researchers, professionals, and students alike.

Phytotherapy Research, a distinguished journal published by Wiley, stands at the forefront of the pharmacological literature, delivering essential insights into the therapeutic potential of plant-based interventions. With its ISSN 0951-418X and E-ISSN 1099-1573, the journal has firmly established itself since its inception in 1987, now converging into its 2024 volume. Notably positioned in the Q1 category of Pharmacology and ranked #22 out of 313 journals in the field, it boasts a remarkable 93rd percentile rating according to Scopus. While the journal adheres to subscription-based access, it remains a crucial repository of high-quality research findings that support the understanding and advancement of herbal medicines and phytotherapeutics. This journal serves as an invaluable resource for researchers, healthcare professionals, and students alike, fostering a deeper exploration of the synergistic relationship between nature and medicine and promoting evidence-based practices in the field.

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Drug Research, published by GEORG THIEME VERLAG KG, is a pivotal journal housed in the vibrant realm of pharmacology and drug discovery. With a commitment to advancing the understanding of medicinal substances, this journal serves as an essential resource for researchers, professionals, and students dedicated to the field. The journal boasts an ISSN of 2194-9379 and an E-ISSN of 2194-9387, reflecting its dual commitment to print and digital accessibility. Despite its status as a Q3 journal in both Drug Discovery and Miscellaneous Medicine categories as of 2023, it continues to offer valuable insights with a focus on the latest innovations, methodologies, and findings in drug research. Based in Germany, Drug Research promotes scholarly communication and collaboration within the scientific community, ensuring that its contributions remain impactful in shaping future therapeutic discoveries. The journal is indexed in relevant databases, enhancing its visibility and reach, thus fostering a robust academic dialogue.

Journal of Inflammation Research, published by Dove Medical Press Ltd, is a premier open-access journal dedicated to advancing the field of immunology and allergy, with a particular focus on the biological mechanisms underlying inflammation. Since its inception in 2008, this journal has provided a vital platform for researchers to share their findings and foster collaboration within the global scientific community. With an impressive 2023 impact factor placing it in the Q2 category for both Immunology and Immunology and Allergy, the journal has consistently maintained its relevance and high academic standards, ranking #100 in Medicine (Immunology and Allergy) and #118 in Immunology (Immunology and Microbiology) according to Scopus metrics. The E-ISSN 1178-7031 allows for easy access to a plethora of pioneering research articles, reviews, and clinical studies that address contemporary issues in inflammation and immunity. As a leading resource for researchers, professionals, and students alike, Journal of Inflammation Research is committed to facilitating the dissemination of groundbreaking discoveries that contribute to improved therapeutic strategies and health outcomes.

Natural Products Journal, a leading publication by Bentham Science Publishers, primarily focuses on the rapidly evolving field of Natural Products and their applications in Complementary and Alternative Medicine as well as Drug Discovery. With an ISSN of 2210-3155 and an E-ISSN of 2210-3163, this journal serves as an essential platform for researchers, professionals, and students dedicated to exploring the critical role of natural compounds in health and medicine. Since its inception in 2011, it has consolidated its reputation, achieving a Q3 ranking in Complementary and Alternative Medicine and a Q4 ranking in Drug Discovery as of 2023, illustrating its growing influence within the academic community. Although it currently does not operate as an Open Access journal, it remains a vital resource for cutting-edge research and developments in natural products, offering insightful contributions that pave the way for innovative therapeutic strategies. Located in the Netherlands, the journal is pivotal for those looking to stay at the forefront of research in natural substances and their multifaceted applications.

The International Journal of Inflammation, published by HINDAWI LTD, serves as a vital resource within the field of Immunology and Allergy. With an established Open Access policy since 2010, this journal provides unrestricted access to cutting-edge research, fostering collaboration and dissemination of knowledge among researchers, professionals, and students. The journal’s ISSN is 2090-8040 and E-ISSN 2042-0099. Situated in the United States with administrative offices in England, it has consistently contributed to the academic community, evidenced by its ranking in the Q3 category for 2023, reflecting its significant presence in the field. Covering a wide range of topics from the molecular basis of inflammation to clinical implications and treatment strategies, the journal engages with the latest developments and current debates. With a Scopus rank of 145 out of 233 in the category of Medicine, its percentile rank of 37th indicates its influence and relevance in contemporary research. As the journal continues to evolve from its convergence years spanning from 2012 to 2024, it remains committed to advancing knowledge and innovation in inflammation research.